Literature DB >> 29955147

Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions.

Bérengère Dadone-Montaudié1, Laurent Alberti2,3, Adeline Duc3, Lucile Delespaul4,5,6, Tom Lesluyes4,5,6, Gaëlle Pérot7, Agnès Lançon3, Sandrine Paindavoine3, Ilaria Di Mauro1, Jean-Yves Blay2,8, Arnaud de la Fouchardière3, Frédéric Chibon4,7,6, Marie Karanian3, Gaëtan MacGrogan7, Valérie Kubiniek1, Frédérique Keslair1, Nathalie Cardot-Leccia9, Audrey Michot10, Virginie Perrin11, Yanis Zekri11, Jean-Michel Coindre5,7, Franck Tirode2,11, Florence Pedeutour1, Dominique Ranchère-Vince3, François Le Loarer5,7, Daniel Pissaloux12,13.   

Abstract

Dermatofibrosarcoma protuberans is underlined by recurrent collagen type I alpha 1 chain-platelet-derived growth factor B chain (COL1A1-PDGFB) fusions but ~ 4% of typical dermatofibrosarcoma protuberans remain negative for this translocation in routine molecular screening. We investigated a series of 21 cases not associated with the pathognomonic COL1A1-PDGFB fusion on routine fluorescence in situ hybridization (FISH) testing. All cases displayed morphological and clinical features consistent with the diagnosis of dermatofibrosarcoma protuberans. RNA-sequencing analysis was successful in 20 cases. The classical COL1A1-PDGFB fusion was present in 40% of cases (n = 8/20), and subsequently confirmed with a COL1A1 break-apart FISH probe in all but one case (n = 7/8). 55% of cases (n = 11/20) displayed novel PDGFD rearrangements; PDGFD being fused either to the 5' part of COL6A3 (2q37.3) (n = 9/11) or EMILIN2 (18p11) (n = 2/11). All rearrangements led to in-frame fusion transcripts and were confirmed at genomic level by FISH and/or array-comparative genomic hybridization. PDGFD-rearranged dermatofibrosarcoma protuberans presented clinical outcomes similar to typical dermatofibrosarcoma protuberans. Notably, the two EMILIN2-PDGFD cases displayed fibrosarcomatous transformation and homozygous deletions of CDKN2A at genomic level. We report the first recurrent molecular variant of dermatofibrosarcoma protuberans involving PDGFD, which functionally mimic bona fide COL1A1-PDGFB fusions, leading presumably to a similar autocrine loop-stimulating PDGFRB. This study also emphasizes that COL1A1-PDGFB fusions can be cytogenetically cryptic on FISH testing in a subset of cases, thereby representing a diagnostic pitfall that pathologists should be aware of.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29955147     DOI: 10.1038/s41379-018-0089-4

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

Review 1.  Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans.

Authors:  Takeshi Iwasaki; Hidetaka Yamamoto; Yoshinao Oda
Journal:  Curr Treat Options Oncol       Date:  2019-03-14

2.  Detection of sarcoma fusions by a next-generation sequencing based-ligation-dependent multiplex RT-PCR assay.

Authors:  Marie-Delphine Lanic; François Le Loarer; Vinciane Rainville; Vincent Sater; Mathieu Viennot; Ludivine Beaussire; Pierre-Julien Viailly; Emilie Angot; Isabelle Hostein; Fabrice Jardin; Philippe Ruminy; Marick Laé
Journal:  Mod Pathol       Date:  2022-01-24       Impact factor: 7.842

3.  Coamplification of 12q15 and 12p13 and homozygous CDKN2A/2B deletion: synergistic role of fibrosarcomatous transformation in dermatofibrosarcoma protuberans with a cryptic COL1A1-PDGFB fusion.

Authors:  Yang Lu; Tao Li; Min Chen; Heng Peng; Tianhai Du; Yan Qiu; Hongying Zhang
Journal:  Virchows Arch       Date:  2022-02-16       Impact factor: 4.535

Review 4.  Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck.

Authors:  Esther Baranov; Jason L Hornick
Journal:  Head Neck Pathol       Date:  2020-01-16

5.  PDGFB RNA in situ hybridization for the diagnosis of dermatofibrosarcoma protuberans.

Authors:  Jeffrey M Cloutier; Grace Allard; Gregory R Bean; Jason L Hornick; Gregory W Charville
Journal:  Mod Pathol       Date:  2021-03-24       Impact factor: 7.842

6.  Comprehensive analysis of transcriptome characteristics and identification of TLK2 as a potential biomarker in dermatofibrosarcoma protuberans.

Authors:  Xiao Zhang; Di Sun; Haiyan Zheng; Yamin Rao; Yuqi Deng; Xiao Liang; Jun Chen; Jun Yang
Journal:  Front Genet       Date:  2022-09-05       Impact factor: 4.772

7.  Novel TNC-PDGFD fusion in fibrosarcomatous dermatofibrosarcoma protuberans: a case report.

Authors:  Yuan Chen; Ying-Zhou Shi; Xiao-He Feng; Xiao-Tong Wang; Xiang-Lei He; Ming Zhao
Journal:  Diagn Pathol       Date:  2021-07-13       Impact factor: 2.644

8.  Molecular profiling of soft-tissue sarcomas with FoundationOne® Heme identifies potential targets for sarcoma therapy: a single-centre experience.

Authors:  Susanne Scheipl; Iva Brcic; Tina Moser; Stefan Fischerauer; Jakob Riedl; Marko Bergovec; Maria Smolle; Florian Posch; Armin Gerger; Martin Pichler; Herbert Stoeger; Andreas Leithner; Ellen Heitzer; Bernadette Liegl-Atzwanger; Joanna Szkandera
Journal:  Ther Adv Med Oncol       Date:  2021-07-25       Impact factor: 8.168

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.